Intellia Therapeutics, Inc., a genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, has moved to its new lab facilities in Cambridge, MA.   “The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Nessan Bermingham, Ph.D., chief executive officer and founder, In...